<DOC>
	<DOC>NCT01418261</DOC>
	<brief_summary>The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.</brief_summary>
	<brief_title>SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Individual is ≥ 18 and ≤ 80 years old at time of randomization. Individual is receiving a stable medication regimen including full tolerated doses of 3 or more antihypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 2 weeks prior to screening) that is expected to be maintained without changes for at least 6 months. Individual has an office systolic blood pressure (SBP) of ≥ 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit Individual has an estimated glomerular filtration rate (eGFR) of &lt; 45 mL/min/1.73 m2 Individual has an Ambulatory Blood Pressure Monitoring (ABPM) 24 hour average SBP &lt; 135 mmHg Individual has type 1 diabetes mellitus Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea. Individual has primary pulmonary hypertension. Individual is pregnant, nursing or planning to be pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>uncontrolled hypertension</keyword>
	<keyword>renal denervation</keyword>
</DOC>